Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Reporting results of cancer treatment

1981 • 7,916 citations

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1961 • 685 citations

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1991 • 513 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

1992 • 363 citations

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

1996 • 206 citations

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.

1991 • 165 citations

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1987 • 155 citations

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

1994 • 144 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

1988 • 131 citations

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

1992 • 67 citations

Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base

1993 • 44 citations

Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease.

1987 • 30 citations

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group

1993 • 29 citations

Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

1988 • 28 citations

Second line chemotherapy in small cell lung cancer

1989 • 28 citations

Phase II study of 1,2,4-triglycidylurazol (TGU) previously untreated and treated patients with small cell lung cancer

1987 • 11 citations

Management of small-cell lung cancer

1994 • 9 citations

Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide

1990 • 9 citations

Strategies for new drug identification in small cell lung cancer

1993 • 4 citations